PRRUF News and Press, Immutep Limited

2025-09-12 11:44:56 ET ... Read the full article on Seeking Alpha For further details see: Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade)

2025-05-08 08:46:59 ET Summary Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches. IMMP is well-capitalized with $146.3 million in liquidity, e...

2025-01-28 16:37:29 ET Summary Immutep Limited remains a “Buy” due to promising pipeline updates and strong financials, despite inherent high-risk/high-reward dynamics. Key trials for eftilagimod show encouraging results, particularly in non-small cell lung cancer an...